Akli S - Search Results

1

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. Duong MT, et al. Among authors: akli s. PLoS Genet. 2012;8(3):e1002538. doi: 10.1371/journal.pgen.1002538. Epub 2012 Mar 29. PLoS Genet. 2012. PMID: 22479189 Free PMC article.

2

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Wingate H, Bedrosian I, Akli S, Keyomarsi K. Wingate H, et al. Among authors: akli s. Cell Cycle. 2003 Sep-Oct;2(5):461-6. Cell Cycle. 2003. PMID: 12963845

3

Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.

Akli S, Keyomarsi K. Akli S, et al. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47. Cancer Biol Ther. 2003. PMID: 14508079 Review.

4

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome.

Akli S, Keyomarsi K. Akli S, et al. Breast Cancer Res. 2004;6(5):188-91. doi: 10.1186/bcr905. Epub 2004 Jul 7. Breast Cancer Res. 2004. PMID: 15318923 Free PMC article.

5

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Akli S, et al. Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145171 Free PMC article.

6

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Akli S, et al. Cancer Res. 2011 May 1;71(9):3377-86. doi: 10.1158/0008-5472.CAN-10-4086. Epub 2011 Mar 8. Cancer Res. 2011. PMID: 21385896 Free PMC article.

7

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Duong MT, et al. Among authors: akli s. Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16. Cancer Res. 2013. PMID: 23955388 Free PMC article.

8

A novel interaction between HER2/neu and cyclin E in breast cancer.

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. Mittendorf EA, et al. Among authors: akli s. Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10. Oncogene. 2010. PMID: 20453888 Free PMC article.

9

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. Caruso JA, et al. Among authors: akli s. Oncogene. 2015 Jul;34(27):3556-67. doi: 10.1038/onc.2014.284. Epub 2014 Sep 8. Oncogene. 2015. PMID: 25195861 Free PMC article.

10

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Akli S, et al. Cancer Res. 2004 May 1;64(9):3198-208. doi: 10.1158/0008-5472.can-03-3672. Cancer Res. 2004. PMID: 15126360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters